{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041275","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.864812+00:00","generated_at":"2026-05-16T22:14:58.307914+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Galectin Therapeutics presents NAVIGATE trial: belapectin reduces varices, biomarkers improve","bullets":["Belapectin 2 mg/kg reduced new varices vs placebo across all ELF risk categories at 18 months; in highest risk (ELF>11.3): 22.7% vs 42.9%.","Pro-C3 biomarker showed >50% reduction from baseline at 18 months with belapectin 2 mg/kg vs placebo (mean -6.4 vs -4.5 ng/mL).","Higher proportion of belapectin 2 mg/kg patients achieved ≥20% reduction in YKL-40 (33.8% vs 23.1%); fewer had ≥20% PRO-C4 increase (3% vs 13%).","At 36 months, cumulative new varices incidence 12.4% (belapectin 2 mg/kg) vs 23.4% (placebo), sustained benefit.","Safety profile encouraging; adverse events and serious adverse events comparable to placebo, no drug-related SAEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041275","json":"https://secwatch.observer/filing/0001140361-25-041275.json","markdown":"https://secwatch.observer/filing/0001140361-25-041275.md","text":"https://secwatch.observer/filing/0001140361-25-041275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125041275/0001140361-25-041275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125041275/ny20058530x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:14:58.307914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}